MARCKS mediates vascular contractility through regulating interactions between voltage-gated Ca 2+ channels and PIP 2

Phosphatidylinositol 4,5-bisphosphate (PIP ) acts as substrate and unmodified ligand for Gq-protein-coupled receptor signalling in vascular smooth muscle cells (VSMCs) that is central for initiating contractility. The present work investigated how PIP might perform these two potentially conflicting...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vascular pharmacology 2020-09, Vol.132, p.106776
Hauptverfasser: Jahan, Kazi S, Shi, Jian, Greenberg, Harry Z E, Khavandi, Sam, Baudel, Miguel Martín-Aragón, Barrese, Vincenzo, Greenwood, Iain A, Albert, Anthony P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 106776
container_title Vascular pharmacology
container_volume 132
creator Jahan, Kazi S
Shi, Jian
Greenberg, Harry Z E
Khavandi, Sam
Baudel, Miguel Martín-Aragón
Barrese, Vincenzo
Greenwood, Iain A
Albert, Anthony P
description Phosphatidylinositol 4,5-bisphosphate (PIP ) acts as substrate and unmodified ligand for Gq-protein-coupled receptor signalling in vascular smooth muscle cells (VSMCs) that is central for initiating contractility. The present work investigated how PIP might perform these two potentially conflicting roles by studying the effect of myristoylated alanine-rich C kinase substrate (MARCKS), a PIP -binding protein, on vascular contractility in rat and mouse mesenteric arteries. Using wire myography, MANS peptide (MANS), a MARCKS inhibitor, produced robust contractions with a pharmacological profile suggesting a predominantly role for L-type (CaV1.2) voltage-gated Ca channels (VGCC). Knockdown of MARCKS using morpholino oligonucleotides reduced contractions induced by MANS and stimulation of α -adrenoceptors and thromboxane receptors with methoxamine (MO) and U46619 respectively. Immunocytochemistry and proximity ligation assays demonstrated that MARCKS and CaV1.2 proteins co-localise at the plasma membrane in unstimulated tissue, and that MANS and MO reduced these interactions and induced translocation of MARCKS from the plasma membrane to the cytosol. Dot-blots revealed greater PIP binding to MARCKS than CaV1.2 in unstimulated tissue, with this binding profile reversed following stimulation by MANS and MO. MANS evoked an increase in peak amplitude and shifted the activation curve to more negative membrane potentials of whole-cell voltage-gated Ca currents, which were prevented by depleting PIP levels with wortmannin. This present study indicates for the first time that MARCKS is important regulating vascular contractility and suggests that disinhibition of MARCKS by MANS or vasoconstrictors may induce contraction through releasing PIP into the local environment where it increases voltage-gated Ca channel activity.
doi_str_mv 10.1016/j.vph.2020.106776
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_32707323</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32707323</sourcerecordid><originalsourceid>FETCH-pubmed_primary_327073233</originalsourceid><addsrcrecordid>eNqFjktLxDAUhYMgzvj4AW7k7qU1D0napRRFEWGYcT_caa9phk5akrQy_94qunZ1OJyPw8fYteC54ELf7fNpaHPJ5XfXxugTthSFKTOl78sFO49xz7koCl2esYWShhsl1ZKNbw_r6nUDB2ocJoowYazHDgPUvU8B6-Q6l46Q2tCPtoVAdl6T8xacT_QD9D7CjtInkYep7xJayux81kCFIG-hbtF76iKgb2D1sgJ5yU4_sIt09ZsX7Obp8b16zoZxN5tsh-AOGI7bP0_1L_AFKwxPOw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>MARCKS mediates vascular contractility through regulating interactions between voltage-gated Ca 2+ channels and PIP 2</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Jahan, Kazi S ; Shi, Jian ; Greenberg, Harry Z E ; Khavandi, Sam ; Baudel, Miguel Martín-Aragón ; Barrese, Vincenzo ; Greenwood, Iain A ; Albert, Anthony P</creator><creatorcontrib>Jahan, Kazi S ; Shi, Jian ; Greenberg, Harry Z E ; Khavandi, Sam ; Baudel, Miguel Martín-Aragón ; Barrese, Vincenzo ; Greenwood, Iain A ; Albert, Anthony P</creatorcontrib><description>Phosphatidylinositol 4,5-bisphosphate (PIP ) acts as substrate and unmodified ligand for Gq-protein-coupled receptor signalling in vascular smooth muscle cells (VSMCs) that is central for initiating contractility. The present work investigated how PIP might perform these two potentially conflicting roles by studying the effect of myristoylated alanine-rich C kinase substrate (MARCKS), a PIP -binding protein, on vascular contractility in rat and mouse mesenteric arteries. Using wire myography, MANS peptide (MANS), a MARCKS inhibitor, produced robust contractions with a pharmacological profile suggesting a predominantly role for L-type (CaV1.2) voltage-gated Ca channels (VGCC). Knockdown of MARCKS using morpholino oligonucleotides reduced contractions induced by MANS and stimulation of α -adrenoceptors and thromboxane receptors with methoxamine (MO) and U46619 respectively. Immunocytochemistry and proximity ligation assays demonstrated that MARCKS and CaV1.2 proteins co-localise at the plasma membrane in unstimulated tissue, and that MANS and MO reduced these interactions and induced translocation of MARCKS from the plasma membrane to the cytosol. Dot-blots revealed greater PIP binding to MARCKS than CaV1.2 in unstimulated tissue, with this binding profile reversed following stimulation by MANS and MO. MANS evoked an increase in peak amplitude and shifted the activation curve to more negative membrane potentials of whole-cell voltage-gated Ca currents, which were prevented by depleting PIP levels with wortmannin. This present study indicates for the first time that MARCKS is important regulating vascular contractility and suggests that disinhibition of MARCKS by MANS or vasoconstrictors may induce contraction through releasing PIP into the local environment where it increases voltage-gated Ca channel activity.</description><identifier>EISSN: 1879-3649</identifier><identifier>DOI: 10.1016/j.vph.2020.106776</identifier><identifier>PMID: 32707323</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Calcium Channel Blockers - pharmacology ; Calcium Channels, L-Type - drug effects ; Calcium Channels, L-Type - metabolism ; Male ; Mesenteric Artery, Superior - metabolism ; Mice, 129 Strain ; Muscle, Smooth, Vascular - drug effects ; Muscle, Smooth, Vascular - metabolism ; Myristoylated Alanine-Rich C Kinase Substrate - antagonists &amp; inhibitors ; Myristoylated Alanine-Rich C Kinase Substrate - genetics ; Myristoylated Alanine-Rich C Kinase Substrate - metabolism ; Peptide Fragments - pharmacology ; Phosphatidylinositol 4,5-Diphosphate - metabolism ; Rats, Wistar ; Signal Transduction ; Vasoconstriction - drug effects ; Vasoconstrictor Agents - pharmacology</subject><ispartof>Vascular pharmacology, 2020-09, Vol.132, p.106776</ispartof><rights>Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32707323$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jahan, Kazi S</creatorcontrib><creatorcontrib>Shi, Jian</creatorcontrib><creatorcontrib>Greenberg, Harry Z E</creatorcontrib><creatorcontrib>Khavandi, Sam</creatorcontrib><creatorcontrib>Baudel, Miguel Martín-Aragón</creatorcontrib><creatorcontrib>Barrese, Vincenzo</creatorcontrib><creatorcontrib>Greenwood, Iain A</creatorcontrib><creatorcontrib>Albert, Anthony P</creatorcontrib><title>MARCKS mediates vascular contractility through regulating interactions between voltage-gated Ca 2+ channels and PIP 2</title><title>Vascular pharmacology</title><addtitle>Vascul Pharmacol</addtitle><description>Phosphatidylinositol 4,5-bisphosphate (PIP ) acts as substrate and unmodified ligand for Gq-protein-coupled receptor signalling in vascular smooth muscle cells (VSMCs) that is central for initiating contractility. The present work investigated how PIP might perform these two potentially conflicting roles by studying the effect of myristoylated alanine-rich C kinase substrate (MARCKS), a PIP -binding protein, on vascular contractility in rat and mouse mesenteric arteries. Using wire myography, MANS peptide (MANS), a MARCKS inhibitor, produced robust contractions with a pharmacological profile suggesting a predominantly role for L-type (CaV1.2) voltage-gated Ca channels (VGCC). Knockdown of MARCKS using morpholino oligonucleotides reduced contractions induced by MANS and stimulation of α -adrenoceptors and thromboxane receptors with methoxamine (MO) and U46619 respectively. Immunocytochemistry and proximity ligation assays demonstrated that MARCKS and CaV1.2 proteins co-localise at the plasma membrane in unstimulated tissue, and that MANS and MO reduced these interactions and induced translocation of MARCKS from the plasma membrane to the cytosol. Dot-blots revealed greater PIP binding to MARCKS than CaV1.2 in unstimulated tissue, with this binding profile reversed following stimulation by MANS and MO. MANS evoked an increase in peak amplitude and shifted the activation curve to more negative membrane potentials of whole-cell voltage-gated Ca currents, which were prevented by depleting PIP levels with wortmannin. This present study indicates for the first time that MARCKS is important regulating vascular contractility and suggests that disinhibition of MARCKS by MANS or vasoconstrictors may induce contraction through releasing PIP into the local environment where it increases voltage-gated Ca channel activity.</description><subject>Animals</subject><subject>Calcium Channel Blockers - pharmacology</subject><subject>Calcium Channels, L-Type - drug effects</subject><subject>Calcium Channels, L-Type - metabolism</subject><subject>Male</subject><subject>Mesenteric Artery, Superior - metabolism</subject><subject>Mice, 129 Strain</subject><subject>Muscle, Smooth, Vascular - drug effects</subject><subject>Muscle, Smooth, Vascular - metabolism</subject><subject>Myristoylated Alanine-Rich C Kinase Substrate - antagonists &amp; inhibitors</subject><subject>Myristoylated Alanine-Rich C Kinase Substrate - genetics</subject><subject>Myristoylated Alanine-Rich C Kinase Substrate - metabolism</subject><subject>Peptide Fragments - pharmacology</subject><subject>Phosphatidylinositol 4,5-Diphosphate - metabolism</subject><subject>Rats, Wistar</subject><subject>Signal Transduction</subject><subject>Vasoconstriction - drug effects</subject><subject>Vasoconstrictor Agents - pharmacology</subject><issn>1879-3649</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFjktLxDAUhYMgzvj4AW7k7qU1D0napRRFEWGYcT_caa9phk5akrQy_94qunZ1OJyPw8fYteC54ELf7fNpaHPJ5XfXxugTthSFKTOl78sFO49xz7koCl2esYWShhsl1ZKNbw_r6nUDB2ocJoowYazHDgPUvU8B6-Q6l46Q2tCPtoVAdl6T8xacT_QD9D7CjtInkYep7xJayux81kCFIG-hbtF76iKgb2D1sgJ5yU4_sIt09ZsX7Obp8b16zoZxN5tsh-AOGI7bP0_1L_AFKwxPOw</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Jahan, Kazi S</creator><creator>Shi, Jian</creator><creator>Greenberg, Harry Z E</creator><creator>Khavandi, Sam</creator><creator>Baudel, Miguel Martín-Aragón</creator><creator>Barrese, Vincenzo</creator><creator>Greenwood, Iain A</creator><creator>Albert, Anthony P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>202009</creationdate><title>MARCKS mediates vascular contractility through regulating interactions between voltage-gated Ca 2+ channels and PIP 2</title><author>Jahan, Kazi S ; Shi, Jian ; Greenberg, Harry Z E ; Khavandi, Sam ; Baudel, Miguel Martín-Aragón ; Barrese, Vincenzo ; Greenwood, Iain A ; Albert, Anthony P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_327073233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Calcium Channel Blockers - pharmacology</topic><topic>Calcium Channels, L-Type - drug effects</topic><topic>Calcium Channels, L-Type - metabolism</topic><topic>Male</topic><topic>Mesenteric Artery, Superior - metabolism</topic><topic>Mice, 129 Strain</topic><topic>Muscle, Smooth, Vascular - drug effects</topic><topic>Muscle, Smooth, Vascular - metabolism</topic><topic>Myristoylated Alanine-Rich C Kinase Substrate - antagonists &amp; inhibitors</topic><topic>Myristoylated Alanine-Rich C Kinase Substrate - genetics</topic><topic>Myristoylated Alanine-Rich C Kinase Substrate - metabolism</topic><topic>Peptide Fragments - pharmacology</topic><topic>Phosphatidylinositol 4,5-Diphosphate - metabolism</topic><topic>Rats, Wistar</topic><topic>Signal Transduction</topic><topic>Vasoconstriction - drug effects</topic><topic>Vasoconstrictor Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jahan, Kazi S</creatorcontrib><creatorcontrib>Shi, Jian</creatorcontrib><creatorcontrib>Greenberg, Harry Z E</creatorcontrib><creatorcontrib>Khavandi, Sam</creatorcontrib><creatorcontrib>Baudel, Miguel Martín-Aragón</creatorcontrib><creatorcontrib>Barrese, Vincenzo</creatorcontrib><creatorcontrib>Greenwood, Iain A</creatorcontrib><creatorcontrib>Albert, Anthony P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Vascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jahan, Kazi S</au><au>Shi, Jian</au><au>Greenberg, Harry Z E</au><au>Khavandi, Sam</au><au>Baudel, Miguel Martín-Aragón</au><au>Barrese, Vincenzo</au><au>Greenwood, Iain A</au><au>Albert, Anthony P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MARCKS mediates vascular contractility through regulating interactions between voltage-gated Ca 2+ channels and PIP 2</atitle><jtitle>Vascular pharmacology</jtitle><addtitle>Vascul Pharmacol</addtitle><date>2020-09</date><risdate>2020</risdate><volume>132</volume><spage>106776</spage><pages>106776-</pages><eissn>1879-3649</eissn><abstract>Phosphatidylinositol 4,5-bisphosphate (PIP ) acts as substrate and unmodified ligand for Gq-protein-coupled receptor signalling in vascular smooth muscle cells (VSMCs) that is central for initiating contractility. The present work investigated how PIP might perform these two potentially conflicting roles by studying the effect of myristoylated alanine-rich C kinase substrate (MARCKS), a PIP -binding protein, on vascular contractility in rat and mouse mesenteric arteries. Using wire myography, MANS peptide (MANS), a MARCKS inhibitor, produced robust contractions with a pharmacological profile suggesting a predominantly role for L-type (CaV1.2) voltage-gated Ca channels (VGCC). Knockdown of MARCKS using morpholino oligonucleotides reduced contractions induced by MANS and stimulation of α -adrenoceptors and thromboxane receptors with methoxamine (MO) and U46619 respectively. Immunocytochemistry and proximity ligation assays demonstrated that MARCKS and CaV1.2 proteins co-localise at the plasma membrane in unstimulated tissue, and that MANS and MO reduced these interactions and induced translocation of MARCKS from the plasma membrane to the cytosol. Dot-blots revealed greater PIP binding to MARCKS than CaV1.2 in unstimulated tissue, with this binding profile reversed following stimulation by MANS and MO. MANS evoked an increase in peak amplitude and shifted the activation curve to more negative membrane potentials of whole-cell voltage-gated Ca currents, which were prevented by depleting PIP levels with wortmannin. This present study indicates for the first time that MARCKS is important regulating vascular contractility and suggests that disinhibition of MARCKS by MANS or vasoconstrictors may induce contraction through releasing PIP into the local environment where it increases voltage-gated Ca channel activity.</abstract><cop>United States</cop><pmid>32707323</pmid><doi>10.1016/j.vph.2020.106776</doi></addata></record>
fulltext fulltext
identifier EISSN: 1879-3649
ispartof Vascular pharmacology, 2020-09, Vol.132, p.106776
issn 1879-3649
language eng
recordid cdi_pubmed_primary_32707323
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Calcium Channel Blockers - pharmacology
Calcium Channels, L-Type - drug effects
Calcium Channels, L-Type - metabolism
Male
Mesenteric Artery, Superior - metabolism
Mice, 129 Strain
Muscle, Smooth, Vascular - drug effects
Muscle, Smooth, Vascular - metabolism
Myristoylated Alanine-Rich C Kinase Substrate - antagonists & inhibitors
Myristoylated Alanine-Rich C Kinase Substrate - genetics
Myristoylated Alanine-Rich C Kinase Substrate - metabolism
Peptide Fragments - pharmacology
Phosphatidylinositol 4,5-Diphosphate - metabolism
Rats, Wistar
Signal Transduction
Vasoconstriction - drug effects
Vasoconstrictor Agents - pharmacology
title MARCKS mediates vascular contractility through regulating interactions between voltage-gated Ca 2+ channels and PIP 2
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T17%3A23%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MARCKS%20mediates%20vascular%20contractility%20through%20regulating%20interactions%20between%20voltage-gated%20Ca%202+%20channels%20and%20PIP%202&rft.jtitle=Vascular%20pharmacology&rft.au=Jahan,%20Kazi%20S&rft.date=2020-09&rft.volume=132&rft.spage=106776&rft.pages=106776-&rft.eissn=1879-3649&rft_id=info:doi/10.1016/j.vph.2020.106776&rft_dat=%3Cpubmed%3E32707323%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32707323&rfr_iscdi=true